Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together
A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.
Impacts of Provincial Central Pooling of Basic Medical Insurance on China's Healthcare Ecosystem
Increasing the risk pooling level is essential for reducing regional disparities and improving the efficiency of BMI funds. This change will deeply affect the supply and demand sides of China's healthcare ecosystem.
NRDL+ Policy Watch Debrief: Raising the Bar for Innovation
The April debrief analyzed recent advancements to the NHSA's lifecycle pricing framework and key policy directions for Huiminbao, focusing on their combined effects on the pricing and access pathways for innovative medicines in China.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations
These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
China Local Pilots Expedite Access to Innovative Medicine
These local experiments focus on speeding up clinical trials, broadening payment options, and incentivizing hospital listings to accelerate access to innovative drugs and medical devices.
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market
Bi Jingquan, previously at the helm of the China Food and Drug Administration and instrumental in regulatory overhauls that transformed
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
